ÃÖö¿ø

  • Áø·á°ú

    Ç÷¾×³»°ú

  • Àü¹®Áø·áºÐ¾ß

    ¹éÇ÷º´, °ñ¼öÀÌÇü¼ºÁõÈıº, °ñ¼öÁõ½ÄÁ¾¾ç, Ç÷¾×Áúȯ, Á¶Ç÷¸ð¼¼Æ÷À̽Ä

  • ´ã´çŬ¸®´Ð

    ¹éÇ÷º´¹×¸²ÇÁÁ¾Å¬¸®´Ð

  • °ü·Ã¼¾ÅÍ

    °Ç°­ÁõÁø¼¾ÅÍ(»ç¿ë) , Ç÷¾×¾Ï ¼¾ÅÍ

ÃÖö¿ø

ÃÖö¿ø ±³¼öÀÇ Áø·á½Ã°£Ç¥ Áø·á¿¹¾à

Áø·á°ú/¼¾ÅÍ ¿ù È­ ¼ö ¸ñ ±Ý Åä Àü¹®Áø·á°ú¸ñ
Ç÷¾×³»°ú
¿ÀÈÄ
¿ÀÀü
-
¿ÀÈÄ
¿ÀÀü
- ¹éÇ÷º´, °ñ¼öÀÌÇü¼ºÁõÈıº, °ñ¼öÁõ½ÄÁ¾¾ç, Ç÷¾×Áúȯ, Á¶Ç÷¸ð¼¼Æ÷À̽Ä

ÃÖö¿ø ±³¼öÀÇ »ó¼¼Á¤º¸

ÇзÂ

more
  •  ~   :  °í·Á´ëÇб³ ÀÇ°ú´ëÇÐ ÀÇÇаú
  •  ~   :  °í·Á´ëÇб³ ´ëÇпø ³»°úÇÐÀü°ø ¼®»ç
  •  ~   :  °í·Á´ëÇб³ ´ëÇпø ³»°úÇÐÀü°ø ¹Ú»ç

°æ·Â

more
  • 1995 .03  ~  1998 .04  :  À°±º ±ºÀÇ°ü
  • 1998 .05  ~  2001 .02  :  ÀÓ»ó°­»ç, °í·Á´ëÇб³ ÀÇ·á¿ø
  • 2001 .03  ~  2004 .02  :  Á¶±³¼ö, °í·Á´ëÇб³ ±¸·Îº´¿ø
  • 2004 .03  ~  2009 .02  :  ºÎ±³¼ö, °í·Á´ëÇб³ ±¸·Îº´¿ø
  • 2008 .10  ~  2013 .09  :  °úÀå, ±¸·Îº´¿ø Á¾¾çÇ÷¾×³»°ú
  • 2009 .03  ~   :  ±³¼ö, °í·Á´ëÇб³ ±¸·Îº´¿ø
  • 2012 .02  ~   :  ¼ÒÀå, ±¸·Îº´¿ø °Ç°­ÁõÁø¼¾ÅÍ

ÇÐȸȰµ¿

more
  •  ~   :  (Àü)´ëÇÑÁ¶Ç÷¸ð¼¼Æ÷À̽ÄÇÐȸ ±âȹȫº¸ÀÌ»ç
  •  ~   :  (Çö)´ëÇѳ»°úÇÐȸ Ç÷¾×Á¾¾çºÐ°úÀ§¿ø
  •  ~   :  (Çö)´ëÇѳ»°úÇÐȸ °í½ÃÀ§¿ø
  •  ~   :  (Çö)´ëÇѳ»°úÇÐȸ °£ÇàÀ§¿ø

±¹³»È°µ¿

more
  •  ~   :  (Çö)º¸°Çº¹ÁöºÎ Ç÷¾×°ü¸®À§¿øȸ À§¿ø
  •  ~   :  (Çö)´ëÇÑÀÇÇÐȸÁö ÆíÁýÀ§¿ø

±¹¿ÜÈ°µ¿

more
  • 2006 .05  ~  2008 .02  :  Visiting Fellow, NCI/NIH

³í¹®

more
  • [SCI] (Selection of elderly acute myeloid leukemia patients for intensive chemotherapy: Effectiveness of intensive chemotherapy and subgroup analysis)
  • [SCI] (Early response-based intensification of primary therapy in newly diagnosed multiple myeloma patients who are eligible for autologous stem cell transplantation: phase II study)
  • [SCI] (Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors)
  • [±¹³»³í¹®] ¿Ü·¡¿¡¼­ ö°áÇ̺óÇ÷·Î Áø´ÜµÈ ³²ÀÚ È¯ÀÚÀÇ Æ¯¼º°ú ¾Ç¼ºÁ¾¾çÀÇ À¯º´·ü
  • [SCI] (The oral iron chelator deferasirox induces apoptosis in myeloid leukemia cells by targeting caspase)

Àú¼­

more
  • Ç÷¾×ÇÐ, 2ÆÇ

ÃÖÁ¾¼öÁ¤ÀÏ : 2023.05.08